ASUBIO PHARMA CO., LTD.

February 8, 2010: Announcement of Approval Application in Japan for Manufacturing and Marketing of SUN Y7017 (Memantine) for the Treatment of Alzheimer’s Type Dementia
July 16, 2008: Asubio Pharma’s Inherited Metabolic Disease Agent Biopten Receives Approval for Additional Indication
December 17, 2007: Asubio Pharma’s Congenital Metabolic Abnormalities Agent Biopten Approved by U.S. Food and Drug Administration for Treatment of BH4 Responsive Hyperphenylalaninemia